var data={"title":"Buserelin (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Buserelin (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7546?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=buserelin-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Buserelin (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4804464\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Suprefact;</li>\n      <li>Suprefact Depot</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4804466\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Gonadotropin Releasing Hormone Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4804497\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostate cancer, advanced:</b> <b>Note:</b> Administration of an antiandrogen agent beginning ~7 days prior to initiation of buserelin therapy and continuing for up to ~5 weeks with buserelin therapy is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Suprefact: Initial: 500 mcg every 8 hours for 7 days. Maintenance: 200 mcg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Suprefact Depot</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">2-month: 6.3 mg implant every 2 months (dosage interval may be shortened or extended by a few days if needed)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">3-month: 9.45 mg implant every 3 months (dosage interval may be shortened or extended by a few days if needed)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intranasal: Maintenance: 400 mcg (200 mcg into each nostril) 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Endometriosis:</b> Intranasal: 400 mcg (200 mcg into each nostril) 3 times daily; treatment duration is usually 6 months; maximum duration: 9 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Missed doses:</i> Non-depot formulations: If a dose is missed, take as soon as remembered; if it is almost time for the next dose, skip the missed dose and continue with regular dosing schedule. Do not double doses to make up for a missed dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4804498\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4804499\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4804500\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5950029\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Implant, subcutaneous:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suprefact Depot: 6.3 mg [released over 2 months]; 9.45 mg [released over 3 months]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suprefact: 1 mg/mL (5.5 mL, 10 mL) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, intranasal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suprefact: 1mg/1mL (10 mL) [contains benzalkonium chloride]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11217372\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4804501\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal: Administer at equal time intervals; before first application pump bottle several times in upright position until a uniform mist is released; priming may need to be repeated between uses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: Rotate injection sites; administer at equal time intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Depot formulation: Administer into lateral abdominal wall; a local anesthetic may be administered to injection site prior to implantation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130917\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (meets NIOSH 2016 criteria). This medication is not on the NIOSH (2016) list; however, it meets the criteria for a hazardous drug. Drugs are classified as hazardous based on their properties; the properties of a hazardous drug include one or more of the following characteristics: carcinogenic, teratogenic (or other developmental toxicity), reproductive toxicity, organotoxic at low doses, genotoxic, and/or new agents with structural or toxicity profiles similar to existing hazardous agents. Assess risk to determine appropriate containment strategy (USP-NF 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration. NIOSH recommends double gloving, a protective gown, and (if liquid that could splash) eye/face protection for administration of a topical product; if there is potential for inhalation, respiratory protection is recommended (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F239367\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endometriosis:</b> Nasal solution: Treatment of endometriosis in women who do not require surgical intervention as first-line therapy (length of therapy is usually 6 months, and should not exceed 9 months)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostate cancer, advanced:</b> Injection, nasal solution: Palliative treatment in patients with hormone-dependent advanced prostate cancer (stage D)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4806068\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Suprefact may be confused with Suprane</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">\n          <b>ALERT: Canadian Boxed Warning:</b> Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4804476\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Adverse reaction profile differs based on population/medication and route of administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (20% to 29%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Loss of libido (prostatic cancer 75% to 85%), hot flash (14% to 72%), hypermenorrhea (endometriosis 24%), decreased libido (endometriosis 12%, prostatic cancer 2% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Flatulence (&le;15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Impotence (prostatic cancer 2% to 79%), vaginal dryness (endometriosis 29%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (4% to 28%), weakness (&le;14%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasal mucosa irritation (intranasal 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (&le;6%), hypertension (2% to 5%), peripheral edema (2%), palpitations (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (9%), depression (8%), malaise (&le;8%), emotional lability (7%), insomnia (&le;5%), nervousness (&le;2%), pain (&le;2%), anxiety (1%), hostility (1%), sleep disorder (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Acne vulgaris (endometriosis 5%), dermatological reaction ( 2%), urticaria at injection site (subcutaneous 2%), xeroderma (2%), diaphoresis (&le;2%), pruritus (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Gynecomastia (prostatic cancer &le;3%), weight gain (&le;3%), premenstrual syndrome (endometriosis 2%), weight loss (&le;2%), menstrual disease (endometriosis 1%), hirsutism (endometriosis &le;1%), increased testosterone level (clinical flare; prostatic cancer &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (&le;8%), nausea (&le;7%), increased appetite (&le;5%), sore throat (&le;5%), vomiting (1% to 4%), gastrointestinal fullness (3%), xerostomia (1% to 3%), gastrointestinal distress (&le;3%), dysgeusia (2%), constipation (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Leukorrhea (endometriosis 4%), mastalgia (endometriosis 3%), dyspareunia (endometriosis 2%), vaginal discharge (endometriosis 2%), vaginitis (endometriosis 2%), pelvic pain (endometriosis &le;2%), vaginal discomfort (endometriosis 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Purpura (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application site reaction (intranasal 8%), pain at injection site (subcutaneous 5%), injection site reaction (subcutaneous &le;5%), application site irritation (intranasal 4%), irritation at injection site (subcutaneous 3%), swelling at injection site (subcutaneous 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (&le;5%), myalgia (2% to 5%), limb pain (2%), neck stiffness (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dry nose (intranasal 2%), rhinitis (2%), upper respiratory tract infection (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, abnormality in thinking, accommodation disturbance, altered sense of smell, amnesia, anaphylactic shock, anaphylactoid reaction, anemia, anorexia, arthralgia, arthritis, bleeding at injection site, breast atrophy (endometriosis), breast hypertrophy (endometriosis), cardiac failure, change in appetite, decreased bone mineral density, decreased glucose tolerance, drowsiness, dry eye syndrome, dyslipidemia, dyspnea, ear disease, eczema, ejaculatory disorder (prostatic cancer), epistaxis, exacerbation of diabetes mellitus, extrinsic asthma, eye disease, eye irritation, fatigue, fecal incontinence, feminization (prostatic cancer), fever, gastrointestinal pain, genital pain (prostatic cancer; male), genitourinary disease, hyperalgesia, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypersensitivity reaction, increased acid phosphatase (transient), increased plasma estradiol concentration (endometriosis; transient), increased serum bilirubin, increased serum transaminases, increased thirst, lack of concentration, lactation (endometriosis; female), leukopenia, loss of body hair, loss of scalp hair, memory impairment, muscle cramps, musculoskeletal pain, myelofibrosis, myopathy, onychia sicca, oral mucosa ulcer, otalgia, ovarian cyst (endometriosis; during initial phase of therapy), pharyngitis, pituitary neoplasm, rhinorrhea, sensation of eye pressure, skin photosensitivity, skin rash, suicidal tendencies, syncope, tachycardia, testicular atrophy (prostatic cancer), thrombocytopenia, thrombophlebitis, thrombosis, tinnitus, transient blindness (one eye), tremor, urinary retention, vaginal hemorrhage (endometriosis), vasodilatation, vertigo, visual disturbance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4804472\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to buserelin or any component of the formulation; patients with nonhormone-dependent prostate cancer; patients who have undergone orchiectomy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nasal solution: Additional contraindications: Women with undiagnosed abnormal vaginal bleeding; pregnancy; breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4804473\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anemia: Testosterone suppression is associated with the development of anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May cause dizziness, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving). Patients with a history of depression should be monitored for mood changes and managed appropriately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Decreased bone density: <b> [Canadian Boxed Warning]: Prolonged use of a luteinizing hormone releasing hormone (LHRH) agonist may cause decreased bone mineral density and possibly lead to osteoporosis and increased risk of skeletal bone fracture.</b> Fracture risk increases with duration of therapy. Use of buserelin for &gt;6 months or in association with other risk factors may contribute to additional bone loss. Some clinical trial data suggest a partial reversibility of bone mineral loss following therapy discontinuation. Patients at risk for reduced bone density include those with chronic alcohol and/or tobacco use, family history of osteoporosis, and chronic treatment with anticonvulsants or corticosteroids. The benefits and risks of potential buserelin therapy should be considered before treatment is initiated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Disease flare: <b>[Canadian Boxed Warning]: A transient (usual duration &lt;10 days) exacerbation of the signs and symptoms of the disease process may be observed with the initiation of therapy.</b> Prostate cancer patients may experience worsening or new onset bone pain, neuropathy, hematuria, ureteral or bladder outlet obstruction, hydronephrosis, lymphostasis, or thrombosis with pulmonary embolus; cases of spinal cord compression possibly contributing to paralysis with or without complications have also been reported. Caution and close monitoring should be used in patients with vertebral metastases who are at risk for lesion exacerbation with possible spinal cord compression; Most buserelin studies were conducted without concomitant antiandrogen therapy, although in some studies, antiandrogen therapy was initiated 7 days prior to beginning buserelin and continued for 4 to 5 weeks with buserelin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions (including pruritus, rash, urticaria, allergic asthma with dyspnea, and local erythema) have been observed; anaphylactic/anaphylactoid shock have been reported rarely. Removal of buserelin depot implant may be necessary for severe reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypogonadism: Hypogonadism is an anticipated effect of androgen deprivation therapy; reversal of hypogonadism induced by therapy has not been established in this patient population.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pituitary adenoma: The development of pituitary adenomas may rarely be seen with long-term therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Androgen-deprivation therapy may increase the risk for cardiovascular disease (Levine 2010). Androgen deprivation may increase the QT interval (on ECG); avoid use in patients with congenital long QT syndrome; consider risk:benefit ratio in patients with concomitant antiarrhythmic therapy, electrolyte imbalances or heart failure. Correct electrolyte imbalances prior to initiation of therapy. Discontinue therapy if QT interval prolongation occurs. Increases in blood pressure (including hypertensive crisis) may occur in patients with preexisting hypertension; monitor blood pressure regularly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Reduced glucose tolerance and loss of blood glucose control have been noted in rare cases. Use caution in patients with diabetes; monitor blood glucose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Endometriosis: A transient exacerbation of the signs/symptoms may be associated with the initiation of therapy (worsening clinical condition may require discontinuation or surgical intervention). Oral contraceptives should be discontinued prior to starting therapy; use of a nonhormonal contraceptive is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Urinary obstruction: In patients with prostate cancer, a transient increase in patient symptoms may occur early in therapy. Monitor for signs of urinary obstruction or retention.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Experienced physician: <b>[Canadian Boxed Warning]: Should be prescribed by a physician experienced in the use of hormonal therapy in endometriosis and prostate cancer, and administered under the supervision of a health care provider.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298911\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4804483\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8867&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Choline C 11: Luteinizing Hormone-Releasing Hormone Analogs may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corifollitropin Alfa: Luteinizing Hormone-Releasing Hormone Analogs may enhance the therapeutic effect of Corifollitropin Alfa. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Luteinizing Hormone-Releasing Hormone Analogs may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4804469\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buserelin is contraindicated in pregnant women. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patients should employ a nonhormonal method of contraception during therapy. To exclude preexisting pregnancy, begin treatment on the first or second day of menses; if there is doubt, a pregnancy test is recommended. Ovulation may occur with a missed dose; in the event a patient conceives, therapy should be discontinued.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21121941\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buserelin is contraindicated in breast-feeding women.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Small amounts of buserelin can be detected in breast milk. Contains benzyl alcohol, which has been associated with gasping syndrome in premature infants.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4804504\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood glucose levels (baseline then periodically thereafter in patients with diabetes); blood pressure (in hypertensive patients); mood changes or signs/symptoms of depression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostate cancer: Serum testosterone levels (4 to 6 weeks after initiation of therapy and every 3 months thereafter), prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), bone scan, signs/symptoms of obstructive uropathy (if indicated consider CT scan, IV pyelogram, or ultrasound); digital rectal exam; ECG (in patients at risk for QT prolongation); serum electrolytes (calcium, magnesium and potassium; baseline and then as indicated); cardiovascular risk assessment (prior to treatment) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endometriosis: Serum estradiol levels</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4804487\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Synthetic peptide analog of gonadotropin hormone releasing hormone (GnRH) with a magnified GnRH agonist effect and an extended duration of activity. Following an initial rise in the pituitary gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH), chronic administration of buserelin results in a sustained suppression of LH and FSH and interferes with the production of ovarian and testicular steroids. Eventually, a decline in gonadal steroids to castration levels is observed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4804489\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: 3-month depot implant: Mean time until testosterone reached castrate levels: 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~15%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Via peptidase to inactive metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: SubQ: 70% (non-depot formulation); Intranasal: 1% to 3%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: SubQ: Immediate release: 80 minutes; Depot implants: 20 to 30 days; Nasal: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 3-month depot: &lt;1 day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~50% as unchanged drug); Feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49056127\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bigonist (FR);</li>\n      <li>Bucel (IN);</li>\n      <li>Busarlin (IN);</li>\n      <li>Metrelef (DE);</li>\n      <li>Profact (DE);</li>\n      <li>Supradopin (IN);</li>\n      <li>Suprecur (AT, DK, FI, GB, HK, IS, JP, MT, NO, SE, TR);</li>\n      <li>Suprefact (AT, AU, BE, CR, DK, DO, ES, FI, FR, GB, GR, GT, HN, HU, IS, IT, KR, LU, MY, NI, NL, NZ, PA, PT, SE, SG, SV, TR, ZA);</li>\n      <li>Suprefact Depo (BG);</li>\n      <li>Suprefact Depot (AR, BR, CR, DO, GT, HN, IL, MX, NI, SV, TH, UY);</li>\n      <li>Suprefact E (TH);</li>\n      <li>Suprfact Depot (PA);</li>\n      <li>Zerelin (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. <i>J Clin Oncol</i>. 2014;32(30):3436-3448.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buserelin-united-states-not-available-drug-information/abstract-text/25199761/pubmed\" target=\"_blank\" id=\"25199761\">25199761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, D&rsquo;Amico AV, Berger P, et al, &ldquo;Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. A Science Advisory from the American Heart Association, American Cancer Society, and American Urological Association,&rdquo; <i>Circulation</i>, 2010, 121:831-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buserelin-united-states-not-available-drug-information/abstract-text/20124128/pubmed\" target=\"_blank\" id=\"20124128\">20124128</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohlsson B, Veress B, Janciauskiene S, et al, &ldquo;Chronic Intestinal Pseudo-Obstruction Due to Buserelin-Induced Formation of Anti-GnRH Antibodies,&rdquo; <i>Gastroenterology</i>, 2007, 132(1):45-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/buserelin-united-states-not-available-drug-information/abstract-text/17241858/pubmed\" target=\"_blank\" id=\"17241858\">17241858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suprefact (buserelin) [product monograph]. Laval, Quebec, Canada: sanofi-aventis Canada Inc; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suprefact Depot (buserelin) [product monograph]. Laval, Quebec, Canada: sanofi-aventis Canada Inc; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8867 Version 87.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F4804464\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F4804466\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F4804497\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F4804498\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F4804499\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F4804500\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F5950029\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11217372\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F4804501\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130917\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F239367\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F4806068\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F4804476\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F4804472\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F4804473\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298911\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F4804483\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F4804469\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21121941\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F4804504\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F4804487\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F4804489\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49056127\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8867|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=buserelin-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Buserelin (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}